<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Press Releases &#8211; Cleveland Clinic Innovations</title>
	<atom:link href="https://davekuhar.github.io/cciinnovations/category/ventures/press-releases/feed/" rel="self" type="application/rss+xml" />
	<link>https://davekuhar.github.io/cciinnovations/</link>
	<description></description>
	<lastBuildDate>Tue, 08 Oct 2019 21:25:19 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=5.4.7</generator>

<image>
	<url>https://davekuhar.github.io/cciinnovations/wp-content/uploads/2019/09/cropped-favicon-clear-125x125.png</url>
	<title>Press Releases &#8211; Cleveland Clinic Innovations</title>
	<link>https://davekuhar.github.io/cciinnovations/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Xealth adds Atrium Health, Cleveland Clinic and MemorialCare to close $14m Series A</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/xealth-adds-atrium-health-cleveland-clinic-and-memorialcare-to-close-14m-series-a/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Thu, 20 Jun 2019 04:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/xealth-adds-atrium-health-cleveland-clinic-and-memorialcare-to-close-14m-series-a/</guid>

					<description><![CDATA[Xealth, the leading platform for connecting digital health, today announced that it has secured an additional $3 million in its Series A financing, bringing the amount raised in this round to $14 million total. New investors Atrium Health, Cleveland Clinic and MemorialCare Innovation Fund join McKesson Ventures, Novartis, Philips, ResMed, Threshold Ventures (formerly DFJ Venture), Providence Ventures, UPMC and Froedtert and the Medical College of Wisconsin health network. Investments from this round will be used to advance the development and deployment of the Xealth platform for digital health programs.]]></description>
										<content:encoded><![CDATA[Xealth, the leading platform for connecting digital health, today announced that it has secured an additional $3 million in its Series A financing, bringing the amount raised in this round to $14 million total. New investors Atrium Health, Cleveland Clinic and MemorialCare Innovation Fund join McKesson Ventures, Novartis, Philips, ResMed, Threshold Ventures (formerly DFJ Venture), Providence Ventures, UPMC and Froedtert and the Medical College of Wisconsin health network. Investments from this round will be used to advance the development and deployment of the Xealth platform for digital health programs.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cleveland Diagnostics Announces Publication of Multicenter IsoPSA Clinical Validation Study Demonstrating Improved Accuracy Over Prostate-Specific Antigen Test</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/cleveland-diagnostics-announces-publication-of-multicenter-isopsa-clinical-validation-study-demonstrating-improved-accuracy-over-prostate-specific-antigen-test/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Tue, 07 May 2019 04:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/cleveland-diagnostics-announces-publication-of-multicenter-isopsa-clinical-validation-study-demonstrating-improved-accuracy-over-prostate-specific-antigen-test/</guid>

					<description><![CDATA[Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary study published earlier in European Urology, demonstrating that the non-invasive, blood-based IsoPSA assay has superior diagnostic accuracy over the current gold standard, prostate-specific antigen (PSA), in detecting high-grade prostate cancer.]]></description>
										<content:encoded><![CDATA[Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary study published earlier in European Urology, demonstrating that the non-invasive, blood-based IsoPSA assay has superior diagnostic accuracy over the current gold standard, prostate-specific antigen (PSA), in detecting high-grade prostate cancer.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Shivom Partners With Cleveland Clinic Spinout Family Care Path</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/shivom-partners-with-cleveland-clinic-spinout-family-care-path/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Thu, 04 Apr 2019 04:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/shivom-partners-with-cleveland-clinic-spinout-family-care-path/</guid>

					<description><![CDATA[Shivom announced today that it has signed an agreement to offer Family Care Path's MyLegacy web-based clinical decision support application to its customers.]]></description>
										<content:encoded><![CDATA[Shivom announced today that it has signed an agreement to offer Family Care Path's MyLegacy web-based clinical decision support application to its customers.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Prevent Biometrics® Acquires Assets of X2 Biosystems, Consolidating Leadership in Head Impact Monitoring</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/prevent-biometrics-acquires-assets-of-x2-biosystems-consolidating-leadership-in-head-impact-monitoring/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Mon, 22 Oct 2018 04:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/prevent-biometrics-acquires-assets-of-x2-biosystems-consolidating-leadership-in-head-impact-monitoring/</guid>

					<description><![CDATA[Prevent Biometrics, the Cleveland Clinic spinoff that developed the first accurate, real-time system for monitoring head impacts in contact sports, today announced that it has acquired the head impact monitoring assets of Seattle-based X2 Biosystems. The transaction brings together the two leading head impact monitoring technologies, Prevent’s Impact Monitor Mouthguard, and X2’s skin patch-based platform.]]></description>
										<content:encoded><![CDATA[Prevent Biometrics, the Cleveland Clinic spinoff that developed the first accurate, real-time system for monitoring head impacts in contact sports, today announced that it has acquired the head impact monitoring assets of Seattle-based X2 Biosystems. The transaction brings together the two leading head impact monitoring technologies, Prevent’s Impact Monitor Mouthguard, and X2’s skin patch-based platform.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/clearflow-announces-additional-positive-us-clinical-trial-results-at-the-2018-nti-critical-care-exposition/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Tue, 29 May 2018 04:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/clearflow-announces-additional-positive-us-clinical-trial-results-at-the-2018-nti-critical-care-exposition/</guid>

					<description><![CDATA[ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) &#038; Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural Effusions and ICU Resources in patients undergoing Cardiac Surgery.”]]></description>
										<content:encoded><![CDATA[ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) &#038; Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural Effusions and ICU Resources in patients undergoing Cardiac Surgery.”]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Merchavia Reports Positive Results in a Breakthrough Trial for Early Prostate Cancer Diagnosis</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/merchavia-reports-positive-results-in-a-breakthrough-trial-for-early-prostate-cancer-diagnosis/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Tue, 29 May 2018 04:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/merchavia-reports-positive-results-in-a-breakthrough-trial-for-early-prostate-cancer-diagnosis/</guid>

					<description><![CDATA[Merchavia Holdings and Investments (TASE: MRHL), an Israeli investment company specializing in early-stage life science sector companies, reports positive results from a successful trial which was conducted Cleveland Clinic, a leading medical center, using IsoPSA, a test developed by CDx (in which Merchavia holds about 8%).]]></description>
										<content:encoded><![CDATA[Merchavia Holdings and Investments (TASE: MRHL), an Israeli investment company specializing in early-stage life science sector companies, reports positive results from a successful trial which was conducted Cleveland Clinic, a leading medical center, using IsoPSA, a test developed by CDx (in which Merchavia holds about 8%).]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/navigate-cardiac-structures-inc-ncsi-reports-excellent-valvular-function-at-1-year-follow-up-of-first-patient-to-receive-gate-tricuspid-valved-stent-via/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Mon, 21 May 2018 04:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/navigate-cardiac-structures-inc-ncsi-reports-excellent-valvular-function-at-1-year-follow-up-of-first-patient-to-receive-gate-tricuspid-valved-stent-via/</guid>

					<description><![CDATA[NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function.]]></description>
										<content:encoded><![CDATA[NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/clearflow-reports-eras-cardiac-surgery-recommends-active-tube-clearance-methodology-in-consensus-statement-presented-at-the-98th-annual-meeting-of-the-american-association-for-thoracic-surgeons/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Tue, 01 May 2018 04:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/clearflow-reports-eras-cardiac-surgery-recommends-active-tube-clearance-methodology-in-consensus-statement-presented-at-the-98th-annual-meeting-of-the-american-association-for-thoracic-surgeons/</guid>

					<description><![CDATA[ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018.]]></description>
										<content:encoded><![CDATA[ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Pulsante® Therapy Awarded Prestigious Forfait Innovation Package to Fast-Track Medical Innovation for Cluster Headache in France</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/pulsante-therapy-awarded-prestigious-forfait-innovation-package-to-fast-track-medical-innovation-for-cluster-headache-in-france/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Mon, 12 Mar 2018 04:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/pulsante-therapy-awarded-prestigious-forfait-innovation-package-to-fast-track-medical-innovation-for-cluster-headache-in-france/</guid>

					<description><![CDATA[Autonomic Technologies, Inc., today announced that the College of the French National Authority for Health (HAS) issued a favorable opinion on a Forfait Innovation package for the Pulsante® SPG Microstimulator System. The award will support a randomized controlled trial for patients suffering from cluster headache.]]></description>
										<content:encoded><![CDATA[Autonomic Technologies, Inc., today announced that the College of the French National Authority for Health (HAS) issued a favorable opinion on a Forfait Innovation package for the Pulsante® SPG Microstimulator System. The award will support a randomized controlled trial for patients suffering from cluster headache.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Prevent Biometrics® Announces Commercial Launch of Head Impact Monitor System, Bringing Advanced Real-Time Monitoring of Concussion Impacts to Sports</title>
		<link>https://davekuhar.github.io/cciinnovations/ventures/prevent-biometrics-announces-commercial-launch-of-head-impact-monitor-system-bringing-advanced-real-time-monitoring-of-concussion-impacts-to-sports/</link>
		
		<dc:creator><![CDATA[ICC Admin]]></dc:creator>
		<pubDate>Tue, 09 Jan 2018 05:00:00 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Ventures]]></category>
		<guid isPermaLink="false">https://cci.sitedistrict.com/general/prevent-biometrics-announces-commercial-launch-of-head-impact-monitor-system-bringing-advanced-real-time-monitoring-of-concussion-impacts-to-sports/</guid>

					<description><![CDATA[Prevent Biometrics, the Cleveland Clinic spinoff that created the first and only head impact monitoring technology to accurately detect potential concussion-causing impacts in real time, announces its newest innovation at the Consumer Electronics Show today: the Gen 1.2 Head Impact Monitor System, bringing advanced, never-before-available head impact analytic capabilities to schools, associations, teams and coaches.]]></description>
										<content:encoded><![CDATA[Prevent Biometrics, the Cleveland Clinic spinoff that created the first and only head impact monitoring technology to accurately detect potential concussion-causing impacts in real time, announces its newest innovation at the Consumer Electronics Show today: the Gen 1.2 Head Impact Monitor System, bringing advanced, never-before-available head impact analytic capabilities to schools, associations, teams and coaches.]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
